{"transactions":[{"id":1099667,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2025-06-30T13:01:13.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable on a cash only basis at any time after the date of issuance and expire 20 days following the earliest to occur of (i) the U.S. Food and Drug Administration (\"FDA\") issuing Breakthrough Therapy designation for elraglusib and (ii) the date that the FDA provides written communication available to the Issuer of its determination as to whether the Issuer may pursue registration for elraglusib using Phase 2 or Phase 3 clinical data."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":71428,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":71428},"source":{"system":"sec-edgar","filing":"0001104659-25-063991","document":"tm2519406-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925063991/tm2519406-2_4seq1.xml","form_type":"4"}},{"id":1099666,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-30T13:01:13.000Z","date":"2025-06-27","kind":"purchase","planned":false,"acquired":true,"shares":71428,"price":7,"value":499996.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a Securities Purchase Agreement (the \"Securities Purchase Agreement\"), dated as of June 25, 2025, between Actuate Therapeutics, Inc. (the \"Issuer\") and certain institutional and accredited investors, Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\") purchased from the Issuer in a private placement 71,428 shares of common stock, par value $0.000001 per share (the \"Common Stock\"), and warrants to purchase 71,428 shares of Common Stock (the \"Warrants\"). The closing of the transactions contemplated by the Securities Purchase Agreement occurred on June 27, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":196428,"source":{"system":"sec-edgar","filing":"0001104659-25-063991","document":"tm2519406-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465925063991/tm2519406-2_4seq1.xml","form_type":"4"}},{"id":1428413,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":2324,"price":8,"value":18592.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":131248,"source":{"system":"sec-edgar","filing":"0001104659-24-091371","document":"tm2422197-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924091371/tm2422197-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1428412,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":17361,"price":8,"value":138888.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":980433,"source":{"system":"sec-edgar","filing":"0001104659-24-091371","document":"tm2422197-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924091371/tm2422197-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1428411,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:46:04.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":5314,"price":8,"value":42512.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The original Form 4 filed on August 14, 2024 is being amended by this Form 4 amendment solely to correct the price reported in column 4 of Table I in the original Form 4, which inadvertently included the incorrect price. This amended report does not report any new transactions and all other information reported in the original Form 4 is correct."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001104659-24-091371","document":"tm2422197-2_4aseq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924091371/tm2422197-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2024-08-14"}},{"id":1434281,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-12","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Aaron G.L. Fletcher"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"The options vest and become exercisable on August 12, 2025, subject to the Mr. Fletcher's continuing service on the Issuer's Board of Directors through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":8,"expiration_date":"2034-08-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":56,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434280,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":3528,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":3528},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":55,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434279,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":26355,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F12","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":26355},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":54,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434278,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":false,"shares":8068,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F11","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"exercise_price":5.27,"underlying":"Common Stock","underlying_shares":8068},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":53,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434277,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":573394,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":573394},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":52,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434276,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":78267,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":78267},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":51,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434275,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":484638,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":484638},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":50,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434274,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":74202,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74202},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":49,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434273,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":2094650,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2094650},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":48,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434272,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":326547,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":326547},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":47,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434271,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":2022029,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2022029},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":46,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434270,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-4 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":309589,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":309589},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":45,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434269,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":44559,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":44559},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":44,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434268,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":332867,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":332867},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":43,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434267,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-3 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":101900,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":101900},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":42,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434266,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":147047,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":147047},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":41,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434265,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":23628,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23628},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":40,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434264,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":176499,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":176499},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":39,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434263,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":54032,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":54032},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":38,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434262,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":153702,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":153702},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":37,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434261,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":61857,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":61857},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":36,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434260,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":462073,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":462073},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434259,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":141457,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":141457},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434258,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":307538,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I QP, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":307538},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434257,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Redeemable Convertible Preferred Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":525797,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":525797},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434256,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Note","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":false,"shares":884427,"ownership":{"direct":false,"nature":"Directly held by Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":884427},"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434255,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":2324,"price":9,"value":20916.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F13","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 3,528 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 2,324 of the warrant shares to pay the exercise price and issuing to Bios Fund II NT the remaining 1,204 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":131248,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434254,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":3528,"price":5.27,"value":18592.56,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":133572,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434253,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":17361,"price":9,"value":156249.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 26,355 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 17,361 of the warrant shares to pay the exercise price and issuing to Bios Fund II QP the remaining 8,994 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":980433,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434252,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":26355,"price":5.27,"value":138890.85,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":997794,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434251,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"sale","planned":false,"acquired":false,"shares":5314,"price":9,"value":47826.0,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F11","text":"On August 12, 2024, in connection with the closing of the Issuer's IPO, the warrant to purchase 8,068 shares of common stock for $5.27 per share was automatically exercised on a cashless basis, resulting in the Issuer withholding of 5,314 of the warrant shares to pay the exercise price and issuing to Bios Fund II the remaining 2,754 shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300143,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434250,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"other","planned":false,"acquired":true,"shares":8068,"price":5.27,"value":42518.36,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":305457,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434249,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":573394,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":573394,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434248,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":78267,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":404814,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434247,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":484638,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."}],"balance_after":2506667,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434246,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":74202,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Each share of Series C Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series C Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":383791,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434245,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":2094650,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":2094650,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434244,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":326547,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":326547,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434243,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":2022029,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":2022029,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434242,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":309589,"ownership":{"direct":false,"nature":"Directly held by Bios Fund III, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Each share of Series B-4 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-4 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":309589,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434241,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":44559,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":130044,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434240,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":332867,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":971439,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434239,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":101900,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Each share of Series B-3 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-3 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":297389,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434238,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":147047,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":300749,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434237,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":23628,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":85485,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434236,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":176499,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":638572,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434235,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":54032,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Each share of Series B-2 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-2 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":195489,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434234,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":153702,"ownership":{"direct":false,"nature":"Directly held by Bios Actuate Co-Invest I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":153702,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434233,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":61857,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II NT, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":61857,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434232,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":462073,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":462073,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434231,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":141457,"ownership":{"direct":false,"nature":"Directly held by Bios Fund II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each share of Series B-1 Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series B-1 Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":141457,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434230,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":307538,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I QP, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":307538,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434229,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":525797,"ownership":{"direct":false,"nature":"Directly held by Bios Fund I, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series A Redeemable Convertible Preferred Stock preferred stock automatically converted into 0.555555 shares of common stock upon the closing of the Issuer's IPO. Each share of Series A Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":525797,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434228,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"purchase","planned":false,"acquired":true,"shares":125000,"price":8,"value":1000000.0,"ownership":{"direct":false,"nature":"Directly held by Bios 2024 Co-Invest, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":125000,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434227,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"purchase","planned":false,"acquired":true,"shares":375000,"price":8,"value":3000000.0,"ownership":{"direct":false,"nature":"Directly held by Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":1259427,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}},{"id":1434226,"issuer":{"id":7370,"kind":"organization","name":"ACTUATE THERAPEUTICS, INC."},"owners":[{"id":36358,"kind":"person","name":"Fletcher Aaron G.L.","position":1,"cik":"0001789490","reported_name":"Fletcher Aaron G.L.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36359,"kind":"person","name":"BIOS Capital Management, LP","position":2,"cik":"0001813845","reported_name":"BIOS Capital Management, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":36360,"kind":"person","name":"BIOS Advisors GP, LLC","position":3,"cik":"0001813844","reported_name":"BIOS Advisors GP, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78016,"kind":"person","name":"BIOS Fund III, LP","position":4,"cik":"0001791917","reported_name":"BIOS Fund III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78017,"kind":"person","name":"BIOS Fund III QP, LP","position":5,"cik":"0001791916","reported_name":"BIOS Fund III QP, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78018,"kind":"person","name":"BIOS Fund III NT, LP","position":6,"cik":"0001791910","reported_name":"BIOS Fund III NT, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78019,"kind":"person","name":"BIOS Actuate Co-Invest I, LP","position":7,"cik":"0001771378","reported_name":"BIOS Actuate Co-Invest I, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78020,"kind":"person","name":"BIOS Actuate Co-Invest II, LP","position":8,"cik":"0001825398","reported_name":"BIOS Actuate Co-Invest II, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78021,"kind":"person","name":"Bios Actuate Co-Invest III, LP","position":9,"cik":"0001956704","reported_name":"Bios Actuate Co-Invest III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78022,"kind":"person","name":"BIOS Equity Partners III, LP","position":10,"cik":"0001831976","reported_name":"BIOS Equity Partners III, LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:49:12.000Z","date":"2024-08-14","kind":"exercise","planned":false,"acquired":true,"shares":884427,"ownership":{"direct":false,"nature":"Directly held by Bios Clinical Opportunity Fund, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a convertible note that was convertible into shares of common stock of the Issuer. The principal amount of the convertible note together with accrued interest was automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's initial public offering (\"IPO\") at a conversion price equal to the initial offering price multiplied by 0.8."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Bios Equity Partners, LP (\"Bios Equity I\") is the general partner of the following entities: Bios Fund I, LP (\"Bios Fund I\"), Bios Fund I QP, LP (\"Bios Fund I QP\") and BP Directors, LP (\"BP Directors\"). Bios Equity Partners II, LP (\"Bios Equity II\") is the general partner of Bios Fund II, LP (\"Bios Fund II\"), Bios Fund II QP, LP (\"Bios Fund II QP\"), Bios Fund II NT, LP (\"Bios Fund II NT\") and Bios Actuate Co-Invest I, LP (\"Bios Actuate Co-Invest I\"). Bios Equity Partners III, LP (\"Bios Equity III\") is the general partner of the following entities: Bios Fund III, LP (\"Bios Fund III\"), Bios Fund III QP, LP (\"Bios Fund III QP\"), Bios Fund III NT, LP (\"Bios Fund III NT\"), Bios Actuate Co-Invest II, LP (\"Bios Actuate Co-Invest II\") and Bios Actuate Co-Invest III, LP (\"Bios Actuate Co-Invest III\"). Bios Equity COF, LP (\"Bios Equity COF\") is the general partner of Bios Clinical Opportunity Fund, LP (\"Bios COF\") and Bios 2024 Co-Invest, LP (\"Bios 2024 Co-Invest\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the \"Bios Equity Entities\") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively."}],"balance_after":884427,"source":{"system":"sec-edgar","filing":"0001104659-24-089822","document":"tm2421559-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1791910/000110465924089822/tm2421559-10_4seq1.xml","form_type":"4"}}]}